SEC filings and other documents

All proposals passed, with strong financials and strategic TPOXX initiatives highlighted.

Q1 saw low revenues but strong liquidity, special dividend, and expanding international reach.

TPOXX drives global health security leadership, robust growth, and strong government partnerships.

TPOXX antiviral franchise and strong government contracts drive robust growth and financials.

2025 delivered strong financials, robust TPOXX demand, and disciplined capital management.

Nine-month 2025 revenue reached $86M, with strong cash and no debt, supporting future growth.

Strong Q2 revenues, new government funding, and pipeline progress amid regulatory review.

TPOXX platform drives global health security leadership, robust growth, and strong financials.

Q1 2025 delivered $6M revenue, strong cash, major U.S. orders, and a $0.60 special dividend.

Record sales, robust cash, and global expansion position the company for future growth.

Strong Q3 revenue, robust order backlog, and pipeline expansion support positive 2025 outlook.

Q2 2024 revenue soared, boosted by major U.S. contracts and global TPOXX expansion.